Probenecid Application Prevents Clinical Symptoms and Inflammation in Experimental Autoimmune Encephalomyelitis

[1]  J. Lees,et al.  The Contribution of Immune and Glial Cell Types in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis , 2014, Multiple sclerosis international.

[2]  B. Fiebich,et al.  The two-hit hypothesis for neuroinflammation: role of exogenous ATP in modulating inflammation in the brain , 2014, Front. Cell. Neurosci..

[3]  I. Jalilian,et al.  Probenecid Blocks Human P2X7 Receptor-Induced Dye Uptake via a Pannexin-1 Independent Mechanism , 2014, PloS one.

[4]  R. Fischer,et al.  Antibody-Mediated Inhibition of TNFR1 Attenuates Disease in a Mouse Model of Multiple Sclerosis , 2014, PloS one.

[5]  Stephen R. Bond,et al.  The pannexins: past and present , 2014, Front. Physiol..

[6]  E. Scemes,et al.  Pannexin 1 involvement in bladder dysfunction in a multiple sclerosis model , 2013, Scientific Reports.

[7]  Sunhee C. Lee,et al.  Contribution of Pannexin1 to Experimental Autoimmune Encephalomyelitis , 2013, PloS one.

[8]  Nathan Robbins,et al.  The History and Future of Probenecid , 2012, Cardiovascular Toxicology.

[9]  L. Hua,et al.  The Gap-junction inhibitor Carbenoxolone suppresses the differentiation of Th17 cells through inhibition of IL-23 expression in antigen presenting cells , 2011, Journal of Neuroimmunology.

[10]  K. Addicks,et al.  Experimental autoimmune encephalomyelitis – achievements and prospective advances , 2011, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[11]  Wei Li,et al.  Role of microglia in CNS inflammation , 2011, FEBS letters.

[12]  P. Insel,et al.  Pannexin-1 hemichannel-mediated ATP release together with P2X1 and P2X4 receptors regulate T-cell activation at the immune synapse. , 2010, Blood.

[13]  J. P. de Rivero Vaccari,et al.  The Pannexin 1 Channel Activates the Inflammasome in Neurons and Astrocytes* , 2009, The Journal of Biological Chemistry.

[14]  D. Spray,et al.  P2X7 receptor-Pannexin1 complex: pharmacology and signaling. , 2008, American journal of physiology. Cell physiology.

[15]  G. Dahl,et al.  Probenecid, a gout remedy, inhibits pannexin 1 channels. , 2008, American journal of physiology. Cell physiology.

[16]  E. Bongarzone,et al.  P2x7 deficiency suppresses development of experimental autoimmune encephalomyelitis , 2008, Journal of Neuroinflammation.

[17]  Amaia M. Arranz,et al.  P2X7 Receptor Blockade Prevents ATP Excitotoxicity in Oligodendrocytes and Ameliorates Experimental Autoimmune Encephalomyelitis , 2007, The Journal of Neuroscience.

[18]  D. Spray,et al.  Pannexin1 is part of the pore forming unit of the P2X7 receptor death complex , 2007, FEBS letters.

[19]  A. Surprenant,et al.  Pannexin‐1 mediates large pore formation and interleukin‐1β release by the ATP‐gated P2X7 receptor , 2006, The EMBO journal.

[20]  G. Dahl,et al.  Pannexin 1 in erythrocytes: Function without a gap , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[21]  H. Dinse,et al.  Spastic Paresis After Perinatal Brain Damage in Rats Is Reduced by Human Cord Blood Mononuclear Cells , 2006, Pediatric Research.

[22]  G. Dahl,et al.  Activation of pannexin 1 channels by ATP through P2Y receptors and by cytoplasmic calcium , 2006, FEBS letters.

[23]  H. Monyer,et al.  Pharmacological properties of homomeric and heteromeric pannexin hemichannels expressed in Xenopus oocytes , 2005, Journal of neurochemistry.

[24]  Amaia M. Arranz,et al.  P2X(7) receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates experimental autoimmune encephalomyelitis. , 2007, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[25]  J. Talbott.  Diagnosis and treatment of gouty arthritis. , 1949, Postgraduate medicine.